Changeflow GovPing Pharma & Drug Safety EPO Patent EP4626865A1: Cyclic Pyrazole Diamide...
Routine Notice Added Final

EPO Patent EP4626865A1: Cyclic Pyrazole Diamide IRE1/XBP1S Activators

Favicon for changeflow.com ChangeBridge: EPO Bulletin - Organic Chemistry (C07D)
Published March 11th, 2026
Detected March 26th, 2026
Email

Summary

The European Patent Office has published patent application EP4626865A1 concerning cyclic pyrazole diamide IRE1/XBP1S activators. The applicant is Protego Biopharma, Inc. This publication relates to new chemical entities and their potential therapeutic applications.

What changed

European Patent Application EP4626865A1, titled 'Cyclic Pyrazole Diamide IRE1/XBP1S Activators,' was published by the EPO on March 11, 2026. The application lists Protego Biopharma, Inc. as the applicant and details specific chemical compounds and their potential use as activators of IRE1/XBP1S pathways, which are implicated in various biological processes and diseases.

This publication represents a new patent filing and does not impose immediate compliance obligations on regulated entities. However, it is relevant for pharmaceutical and biotechnology companies involved in drug discovery and development, particularly those researching IRE1/XBP1S pathways. Companies should monitor the patent prosecution status and consider potential impacts on their own intellectual property strategies and research efforts in this therapeutic area.

Source document (simplified)

← EPO Patent Bulletin

CYCLIC PYRAZOLE DIAMIDE IRE1/XBP1S ACTIVATORS

Publication EP4626865A1 Kind: A1 Mar 11, 2026

Applicants

Protego Biopharma, Inc.

Inventors

LABAUDINIERE, Richard F., TAIT, Bradley Dean, QIU, Huang, PETRASSI, Hank Michael James, QIN, Bo

IPC Classifications

C07D 231/40 20060101AFI20250618BHEP C07D 401/06 20060101ALI20250618BHEP C07D 401/12 20060101ALI20250618BHEP C07D 401/14 20060101ALI20250618BHEP C07D 403/06 20060101ALI20250618BHEP C07D 403/12 20060101ALI20250618BHEP C07D 403/14 20060101ALI20250618BHEP C07D 405/12 20060101ALI20250618BHEP C07D 405/14 20060101ALI20250618BHEP C07D 413/12 20060101ALI20250618BHEP C07D 413/14 20060101ALI20250618BHEP A61P 1/16 20060101ALI20250618BHEP A61P 3/10 20060101ALI20250618BHEP A61P 9/10 20060101ALI20250618BHEP A61P 25/02 20060101ALI20250618BHEP A61P 25/08 20060101ALI20250618BHEP A61P 25/14 20060101ALI20250618BHEP A61P 25/16 20060101ALI20250618BHEP A61P 25/28 20060101ALI20250618BHEP A61P 27/02 20060101ALI20250618BHEP A61K 31/415 20060101ALI20250618BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Classification

Agency
EPO
Published
March 11th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
EP4626865A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Drug Development Patent Filing
Geographic scope
European Union EU

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Topics
Intellectual Property Drug Development

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ChangeBridge: EPO Bulletin - Organic Chemistry (C07D) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.